Comparison of clinical performance of Abbott RealTime high risk HPV test with that of hybrid capture 2 assay in a screening setting

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1446-1451

  Carozzi, F M ^a   Burroni, E ^a   Bisanzi, S ^a   Puliti, D ^a   Confortini, M ^a   ConfortiniGiorgi Rossi, P ^b   Sani, C ^a   Scalisi, A ^c   Chini, F ^b  

^a ISPO   (Italy)

^b Public Health Agency for the Lazio Region   (Italy)

^c ASL 3   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CANCER GRADING; CANCER SCREENING; CONTROLLED STUDY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; HYBRID CAPTURE 2 ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; REAL TIME HIGH RISK HUMAN PAPILLOMAVIRUS TEST; REPRODUCIBILITY; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS STRAIN; WART VIRUS;

ADULT; CERVIX UTERI; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

EID: 79953837321     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02311-10     Document Type: Article

References (25)

1. Arbyn, M., et al. 2006. Chapter 9. Clinical applications of HPV testing: A summary of metaanalyses. Vaccine 24(Suppl. 3):S78-S89. (Pubitemid 44293029)
2. Bouvard, V. A., R. A. Baan, K. A. Straif, Y. Grosse, B. Secretan, F. El Ghissassi, L. Bebraim-Tallaa, N. Guha, C. Freeman, L. Galichat, and V. Cogliano, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. 2009. Special report: Policy. A review of human carcinogens-part B: biological agents. Lancet Oncol. 10:321-322.
3. Bulk, S., et al. 2007. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer 121:361-367. (Pubitemid 46917706)
4. Carozzi, F. M., et al. 2005. Reproducibility of HPV DNA testing by hybrid capture2 in a screening setting. Am. J. Clin. Pathol. 124:716-721.
5. Cohen, J. 1960. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 20:37-46.
6. Cuzick, J., et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. (Pubitemid 44116919)
7. Cuzick, J., et al. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10):K29-K41.
8. Giorgi Rossi, P., S. Bisanzi, I. Paganini, A. Di Iasi, C. Angeloni, A. Scalisi, R. Macis, M. T. Pini, F. Chini, F. M. Carozzi, and the HPV Prevalence Italian Working Group. 2010. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: A population based study. BMC Infect. Dis. 10:214.
9. Halfon, P., D. Benmoura, A. Agostini, H. Khiri, G. Penaranda, A. Martineau, and B. Blanc. 2010. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J. Clin. Virol. 48:246-250.
10. Huang, S., et al. 2009. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45(Suppl 1):S19-23.
11. Kaliterna, V., S. Z. Lepej, and A. Vince. 2009. Comparison between the Abbott RealTime HighRisk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. J. Med. Microbiol. 58:1662-1663.
12. Kjær, S. K., K. Frederiksen, C. Munk, and T. Iftner. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J. Natl. Cancer Inst. 102:1478-1488.
13. Mayrand, M. H. et al. 2007. Human papillomavirus DNA versus Papanicolau screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
14. Meijer, C. J., et al. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
15. Poljak, M., et al. 2009. The Abbott RealTime High Risk HPV test: Comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol. Alp. Panonica Adriat. 18:94-103.
16. Qu, W., et al. 1997. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5-/GP6-primer systems. J. Clin. Microbiol. 35:1304-1310. (Pubitemid 27216785)
17. Ronco, G., et al. 2006. Human papillomavirus testing and liquid-based cytology: Results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J. Natl. Cancer Inst. 98:765-774. (Pubitemid 43983300)
18. Ronco, G., et al. 2006. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: Results at recruitment for a randomised controlled trial. Lancet Oncol. 7:547-555. (Pubitemid 43923665)
19. Ronco, G., P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, A. Del Mistro, B. Ghiringhello, S. Girlando, A. Gillio-Tos, L. De Marco, C. Naldoni, P. Pierotti, R. Rizzolo, P. Schincaglia, M. Zorzi, M. Zappa, N. Segnan, J. Cuzick, and the New Technologies for Cervical Cancer screening (NTCC) Working Group. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol. 11:249-257.
20. Sankaranarayanan, R., et al. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394.
21. Sundström, K., et al. 2010. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol. Biomarkers Prev. 19:2469-2478.
22. Tang, N. S., M. L. Tang, and I. S. Chan. 2003. On tests of equivalence via non-unity relative risk for matched-pair design. Stat. Med. 22:1217-1233. (Pubitemid 36526951)
23. Tang, N., et al. 2009. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J. Clin. Virol. 45(Suppl. 1):S25-S28.
24. Van den Brule, A. J., et al. 2002. GP5-/6-PCR followed by reverse line blot analysis enabled rapid and high throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.
25. Walboomers, J. M., et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19. (Pubitemid 29406813)